How Much Customers Are Spending On Weight Loss Drugs At Med Spas

Weight loss drugs no longer require a doctor’s visit. Now, spas are getting into the game, too — and it’s become a very big business. 

In the U.S., medical aesthetics practices are dominating the GLP-1 market, with more than half of locations offering the drugs, particularly compounded versions of semaglutide and tirzepatide. Many patients are flocking to these locations for the compounded versions of drugs like Ozempic and Mounjaro, which offer a lower price versus the brand name drugs. Compounded drugs average $350 for semaglutide and $485 for tirzeptatide monthly, per health care data and analytics firm Guidepoint Qsight.

“The most striking insight is that 61 percent of patients initiating GLP-1 treatment at aesthetic practices are entirely new to those practices,” said  Erika Sheyn, senior vice president of aesthetics at Guidepoint Qsight. “This underscores how GLP-1 therapies are not only fueling strong revenue performance but also driving unprecedented patient acquisition.” 

Sheyn emphasized that this is also driving an uptick in complementary services that consumers are investing in to address the side effects of weight loss. Specifically, 13 percent of new patients at aesthetics practices on GLP-1s came back within 12 months for an injectable like Botox, energy-based device such as Morpheus8, skin rejuvenation or professional skin care treatment.

While regulations have caused a bit of a slow down, the market is stable and poised for growth, per Sheyn. 

“The aesthetics industry has continued to offer and sell GLP-1 products at meaningful scale. Compounded GLP-1 sales peaked in early 2025 and have since moderated slightly as FDA grace periods expired and new compliance requirements took effect,” she said. “While volumes remain strong, aesthetic practices and compounding partners have been recalibrating operations to align with evolving legal and regulatory standards. This reflects a maturing market for GLP-1 in aesthetics — one where demand remains resilient even amid tighter oversight.” 

Here, a look at the total projected patient spend on GLP-1s at medical aesthetics practices in the U.S. from 2021 to 2025, per Guidepoint Qsight.